Oricell Therapeutics' $110 million pre-IPO financing arrives as the CAR-T market for multiple myeloma intensifies, with GPRC5D emerging as a critical target beyond BCMA. The company's lead asset, OriCAR-017, is an autologous CAR-T therapy targeting GPRC5D for relapsed/refractory multiple myeloma, positioning it against Bristol Myers Squibb's Abecma (ide-cel) and Johnson & Johnson's Carvykti (ciltacabtagene autoleucel), which both target BCMA. GPRC5D offers a potential escape route for patients who relapse after BCMA-directed therapies, a growing clinical need as these earlier CAR-Ts gain broader use.
Strategic positioning in a crowded field
The undisclosed lead investor backing this round suggests institutional confidence in Oricell's ability to navigate both scientific and regulatory hurdles. While Carvykti and Abecma have established commercial footprints, their BCMA focus leaves room for GPRC5D-targeting therapies like OriCAR-017 to capture later-line patients. Oricell's proprietary OriCAR platform aims to enhance persistence and reduce toxicity, key challenges in CAR-T development. The company's Chinese headquarters provide cost advantages in manufacturing but add complexity for global regulatory submissions, particularly in the U.S. and EU.
GPRC5D represents the next logical target in multiple myeloma CAR-T development, but clinical differentiation will determine commercial success.
Pipeline expansion and IPO runway
Beyond OriCAR-017, Oricell plans to use the capital to advance its solid tumor CAR-T programs, an area where CAR-T therapies have historically struggled due to tumor microenvironment barriers. The company has not disclosed specific solid tumor targets, but this move aligns with industry efforts to expand CAR-T beyond hematological malignancies. The pre-IPO round likely values Oricell between $800 million and $1.2 billion, based on comparable CAR-T biotech valuations, setting the stage for a potential 2027 IPO if clinical milestones are met.
The funding comes as Chinese biotechs face increased scrutiny from U.S. regulators, particularly around manufacturing and data integrity. Oricell's ability to demonstrate comparable efficacy and safety to Western-developed GPRC5D CAR-Ts will be critical for global adoption. With Johnson & Johnson and Bristol Myers Squibb also exploring GPRC5D targets, Oricell's first-mover advantage in clinical development could prove decisive, though commercial execution will require partnerships or built-out commercial capabilities.
